Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Synergetic B-cell Immunomodulation in SLE - 2nd Study. (SynBioSe-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03747159
Recruitment Status : Recruiting
First Posted : November 20, 2018
Last Update Posted : February 25, 2021
Sponsor:
Collaborators:
Dutch Kidney Foundation
GlaxoSmithKline
Information provided by (Responsible Party):
Y.K.Onno Teng, Leiden University Medical Center

Brief Summary:
In follow-up of the previous SynBioSe Study the present study is a randomized controlled trial designed to further investigate the long-term clinical and imunological efficacy of combination B-cell targeting by starting treatment with belimumab (anti-BAFF) followed by rituximab(anti-CD20) in lupus nephritis patients.

Condition or disease Intervention/treatment Phase
Lupus Erythematosus, Systemic Drug: Belimumab Injection Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multi-center
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Trial to Investigate the Reset of Humoral Autoimmunity by Combining Belimumab With Rituximab in Severe Systemic Lupus Erythematosus
Actual Study Start Date : October 1, 2018
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : September 2025


Arm Intervention/treatment
Experimental: BLM+RTX treatment arm

Intervention 1 Belimumab injection: subcutaneous weekly injections with 200mg belimumab (BML) for the duration of the entire study period of two years.

Intervention 2 Rituximab infusion: Two intravenously infusions of 1000mg rituximab (RTX) at week 4 and week 6 after the start of belimumab.

Intervention 3: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg*hour/L.

Drug: Belimumab Injection
Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
Other Name: Benlysta subcutaneous injection of 200mg

No Intervention: Standard of Care treatment arm

Intervention 1: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg*hour/L.

Optional intervention: (if patients flare or are non-responders on mycofenolate mofetil + prednisolone) : Two intravenously infusions of 1000mg rituximab at week 4 and week 6 after the start of belimumab.




Primary Outcome Measures :
  1. Treatment failure rate [ Time Frame: 104 weeks ]
    The treatment failure rate will be measured at 104 weeks in both treatment arms with the hypothesis that lower treatment failure rates will be obtained in the RTX+BLM arm.


Secondary Outcome Measures :
  1. Change of disease relevant auto-antibodies present at baseline, in particular anti-dsDNA [ Time Frame: 28 weeks ]
    All disease relevant auto-antibodies will be measured at 28 weeks and compared to baseline with the hypothesis that a better reduction will be obtained in the RTX+BLM arm.

  2. Sustained change of autoantibody production [ Time Frame: 100 weeks ]
    The sustained reduction of pathogenic autoantibodies, in particular anti-dsDNA autoantibodies

  3. Seroconversion of disease relevant auto-antibodies [ Time Frame: 100 weeks ]
    Seroconversion of pathogenic autoantibodies, in particular anti-dsDNA autoantibodies

  4. Change of memory B-cell numbers [ Time Frame: 28 weeks ]
    The detection of (autoreactive) memory B-cells by standardized flowcytometry and in B-cell culture assays

  5. Sustained change of memory B-cell numbers [ Time Frame: 100 weeks ]
    The detection of (autoreactive) memory B-cells by standardized flowcytometry and in B-cell culture assays

  6. Change of immune complex-mediated excessive neutrophil extracellular traps (NET) formation [ Time Frame: 28 weeks ]
    The quantification of ex vivo NET induction with a 3-dimensional, confocal microscopy technique

  7. Sustained change of immune complex-mediated excessive neutrophil extracellular traps (NET) formation [ Time Frame: 100 weeks ]
    The quantification of ex vivo NET induction with a 3-dimensional, confocal microscopy technique

  8. Evaluation of the clinical response [ Time Frame: 100 weeks ]
    The number of partial and complete renal responders in case of lupus nephritis

  9. Evaluation of the clinical response by SLEDAI [ Time Frame: 100 weeks ]
    Patients will be monitored at frequent timepoints by the The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), with a minimum score of 0 and a maximum score of 105, with a higher score indicating a higher disease activity

  10. Evaluation of the clinical response by SLICC [ Time Frame: 100 weeks ]
    SLICC damage score (System Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus) will be assesed at baseline, one year and two years, with a minimum score of 0 and a maximum score of 47, with a higher score indicating more damage

  11. Evaluation of the clinical response by QoL questionnaires [ Time Frame: 100 weeks ]
    QoL questionnaires will be assessed at multiple time points by the SF-36 (ShortForm-36) questionnaire, with a minimum score of 0 and a maximum score of 100, with a higher score indicating a higher quality of life

  12. Evaluation of the clinical response by the amount of moderate and severe flares. [ Time Frame: 100 weeks ]
    Patients will be monitored at frequent timepoint

  13. Evaluation of the clinical response by the ability to reduce concomitant immunosuppression without flares [ Time Frame: 100 weeks ]
    Patients will be monitored at frequent timepoint

  14. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 100 weeks ]
    Patients will be monitored at frequent timepoint



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Have a clinical diagnosis of SLE according to the SLICC criteria 2012
  2. Severe, active SLE disease defined as a situation in which 1 or more of the following criteria are met:

    1. SLEDAI-2K (SLE Disease Activity Index) with 12 or more points
    2. New or worse SLE-related activity of major organs, i.e.: CNS-SLE (includes NPSLE), vasculitis, nephritis, pericarditis and/or myocarditis, myositis, thrombocytopenia < 60, hemolytic anemia < 4.4mmol/L (=7.0g/dL)
    3. high disease activity that requires or warrants induction treatment by switching to or increasing dosage of oral mycophenolate
  3. New, persisting or progressive disease activity despite the use of conventional maintenance immunosuppressive treatment (e.g. mycophenolate or azathioprine)
  4. Positive for relevant SLE-specific autoantibodies defined as a situation in which 1 or more of the following criteria are met:

    1. ANA seropositivity, as defined by a positive ANA-titer ≥ 1:80, before and at screening :

      • Positive test results from 2 independent time points within the study screening period; OR
      • One positive historical test result and 1 positive result during the screening period. Historical documentation of a positive test of ANA (eg, ANA by HEp-2 titer, ANA by ELISA) must include the date of the test.
    2. Anti-DNA seropositivity, as defined by a positive anti-dsDNA serum antibody ≥ 30 IU/mL, before and at screening:

      • Positive test results from 2 independent time points within the study screening period.
      • One positive historical test result and 1 positive result during the screening period. Historical documentation of a positive test of anti-dsDNA (eg, anti-dsDNA by Farr assay or ELISA) must include the date of the test.
  5. Female subjects are eligible to enter the study if she is:

    • Not pregnant or nursing
    • Of non-child-bearing potential (i.e. after hysterectomy, postmenopausal, bilateral ovariectomy or documented bilateral tubal ligation or other permanent female sterilization procedure)
    • in agreement to not become pregnant (if female subjects of childbearing potential) and therefore must be sexually inactive by abstinence or use contraceptive methods with a failure rate of < 1%.

Exclusion Criteria:

  1. Active pregnancy, as proven by a positive urine beta-HCG test or a positive serum beta-HCG
  2. Significant hypogammaglobulinemia (IgG < 4.0 g/L) or an IgA deficiency (IgA < 0.1 g/L)
  3. Immunization with a live vaccine 1 month before screening
  4. Active infection at time of screening, as follows:

    • Hospitalization for treatment of infection within previous 60 days of day 0 of the study
    • Use of parenteral (intravenous of intramuscular) antibiotics (including anti-bacterials, anti-virals, anti-fungals or anti-parasitic agents) within previous 60 days of day 0 of the study
    • Serological evidence of viral hepatitis defined as: patients positive for HbsAg test or HBcAb or a positive hepatitis C antibody not treated with antiviral medication
  5. Have a historically positive HIV test or test positive at screening for HIV
  6. Have a history of a primary immunodeficiency
  7. Have a neutrophil count of < 1.5x10E9/L
  8. Have a significant infection history that in the opinion of the investigator would make the candidate unsuitable for the study
  9. Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies
  10. Have any other clinically significant abnormal laboratory value in the opinion of the investigator
  11. Have current drugs or alcohol abuse or dependence within 365 days prior to Day 0 of the study
  12. Have an active malignant neoplasm or one in the history of the last 5 years, except basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally and with no evidence of metastatic disease for 3 years
  13. Have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months or who, in the investigator's opinion, poses a significant suicide risk
  14. Have any other clinically significant abnormal laboratory value, any intercurrent significant medical or psychiatric illness that in the opinion of the investigator would make the candidate unsuitable for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03747159


Contacts
Layout table for location contacts
Contact: Dr. Y.K.O. Teng, MD, PhD T +31-(0)71-5262148 y.k.o.teng@lumc.nl

Locations
Layout table for location information
Netherlands
University Medical Center Groningen Not yet recruiting
Groningen, Netherlands, 9713 GZ
Contact: Dr. K. de Leeuw, MD, PhD    T +31-(0)50-3612908    k.de.leeuw@umcg.nl   
Principal Investigator: Dr. K. de Leeuw, MD, PhD         
Leiden University Medical Center Recruiting
Leiden, Netherlands, 2333 ZC
Contact: Dr. Y.K.O. Teng, MD, PhD    T +31-(0)71-5262148    y.k.o.teng@lumc.nl   
Principal Investigator: Dr. Y.K.O. Teng, MD, PhD         
Radboud University Medical Center Not yet recruiting
Nijmegen, Netherlands, 6525 GA
Contact: Drs. E.M. van Ommen    T +31-(0)24-3614761    Ellen.vanOmmen@radboudumc.nl   
Principal Investigator: Drs. E.M. van Ommen         
HagaZiekenhuis Not yet recruiting
The Hague, Netherlands, 2545 AA
Contact: Dr. D. Soonawala, MD, PhD    T +31-(0)70-2100000    D.Soonawala@hagaziekenhuis.nl   
Principal Investigator: Dr. D. Soonawala, MD, PhD         
Sponsors and Collaborators
Leiden University Medical Center
Dutch Kidney Foundation
GlaxoSmithKline
Investigators
Layout table for investigator information
Principal Investigator: Dr. Y.K.O. Teng, MD, PhD Leiden University Medical Center
Layout table for additonal information
Responsible Party: Y.K.Onno Teng, Dr. Y.K.O. Teng, Nephrologist, Leiden University Medical Center
ClinicalTrials.gov Identifier: NCT03747159    
Other Study ID Numbers: NL65720.058.18
First Posted: November 20, 2018    Key Record Dates
Last Update Posted: February 25, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Y.K.Onno Teng, Leiden University Medical Center:
systemic lupus erythematosus
lupus nephritis
systemic autoimmune disease
glomerulonephritis
autoimmune glomerulonephritis
membranoproliferative glomerulonephritis
renal insufficiency
renal failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Belimumab
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs